Coronary artery disease is the most common form of heart disease and results from atherosclerotic plaque buildup in coronary arteries, reducing blood flow to the heart. It can present with angina, myocardial infarction, heart failure, or sudden cardiac events.
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
More cancer survivors are living long enough to face lasting cardiovascular effects of treatment. Cardio-oncology clinics are managing heart failure, valvular disease and radiation-related heart disease.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
Recent research shows younger heart disease patients face unique parenting challenges, middle-aged healthy eating protects against cognitive decline, and timing evening meals three hours before bed improves cardiovascular markers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07616544 |
Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization |
NOT_YET_RECRUITING | PHASE3 |
| NCT07614763 |
To Study and Explore the Predictive Effect of Insulin Resistance-related Indicators on In-stent Restenosis After Coronary Stent Implantation |
COMPLETED | |
| NCT07614386 |
Radial Access Data in Vascular Interventions Registry |
RECRUITING | |
| NCT07614230 |
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes |
RECRUITING | PHASE4 |
| NCT07613996 |
Impact of Hyperemic State on Angio-IMR Performance |
RECRUITING | |
| NCT07613060 |
Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization |
NOT_YET_RECRUITING | |
| NCT07612774 |
CAPER-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS |
RECRUITING | PHASE4 |
| NCT07610538 |
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells |
RECRUITING | NA |
| NCT07609381 |
Clinical Information System Impact on Hospitalized Patients With Chronic Disease |
NOT_YET_RECRUITING | |
| NCT07607951 |
Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery |
NOT_YET_RECRUITING | NA |
